Transgene expression in polarized cells
US6465007B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 1, 1999 |
| Grant date | Oct 15, 2002 |
| Priority date | — |
| Expiry date | Jul 1, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The well-differentiated airway epithelium is the principal target tissue for gene therapy for the treatment of CF. However, recent studies have shown that gene delivery vehicles, such as cationic lipid:DNA complexes, can be inefficient at binding to and internalizing into polarized epithelial cells. The present invention provides a method to improve gene therapy by using a compound capable of disrupting tight junctions. In the practice of the invention, the transfection of a biologically active molecule by a cationic amphiphile:biologically active molecule complex or other lipid or viral or nonviral vectors is improved by treating the cells with a class of compounds known in the art as absorption enhancers or tight junction disrupting compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.